Avidity Biosciences amends bylaws to align with universal proxy rules and Delaware law

Avidity Biosciences, Inc.

Board adopted amended and restated bylaws effective December 12, 2023.
Clarifies compliance with SEC Rule 14a-19 for director nominee solicitations.
Updates procedures for stockholder meetings to conform to recent Delaware General Corporation Law changes.
Enhances disclosure requirements for stockholder nominations and proposals, including ownership and relationship details.
Includes technical, modernizing, and clarifying changes.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Avidity Biosciences, Inc.: Amended and restated bylaws to address universal proxy rules, revise stockholder meeting procedures, and enhance disclosure requirements for nominations and proposals (effective 2023-12-12).

Change: bylaw amendment
Effective: 2023-12-12

Exact text from the filing

On December 12, 2023, the board of directors (the "Board") of Avidity Biosciences, Inc. (the “Company”) approved and adopted amended and restated bylaws of the Company (the "Amended and Restated Bylaws"), which became effective the same day.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001599901-23-000099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.